Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
BE reports personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mundipharma, Navamedic, Novo Nordisk and RLS Global outside the submitted work, and grants from Sanofi outside the submitted work
Tirzepatide Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes and chronic weight management
During preparation, confirm that the syringe equal measurement matches the prescribed dose exactly
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin
But the moment you look beneath the surface, orforglipron and tirzepatide reveal themselves as fundamentally different tools designed for different situations, different people, and different stages of the weight management journey
US$ 24.53
US$ 22.15
US$ 25.76
